Composition for Treating Spermatogenesis and Semen Disorders / FPT-20

NCT ID: NCT05399212

Last Updated: 2025-05-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-10-29

Study Completion Date

2022-05-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Research to develop a new, natural-derived formulation that eliminates inflammatory tissue and regenerates new tissue of the lobules, epithelium of the tubules, and connective tissue surrounding the seminiferous tubules in the testes. It restores Leydig cells and Sertoli cells' function (because the inflamed testicles were unable to perform spermatogenesis).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

FPT-20 has stabilized cortisol levels, maintained stable B-lymphocytes in the body, verified by quantitative tests of blood B-lymphocytes and blood cortisol, cut off the chronic inflammation chain, promoted the regeneration of the epithelium of the coiled ducts, and repairs the connective tissue surrounding the coils.

Select a type of flavonoid that has the ability to protect human body cells by destroying toxic proteins. Targeted flavonoids are selected for multiple simultaneous effects, acting as a chemotactic or physiological modifier. Many studies have shown that flavonoids can also act as cell cycle inhibitors, which can also cause cancer cell death at an early stage (at the stage of a few cells). There have been many documents demonstrating that some flavonoids have the ability to kill cancer cells, stabilize stages of cell differentiation, and improve immunity. Flavonoids present in FPT-20 protect and regenerate cells, clean up inflammatory and fibrotic cells, and facilitate the growth of germ cells.

The selected flavonoids in the preparation are also used to regenerate the epithelium in the lumen of the seminiferous tubules, ensure the perfusion of the lobules, and stabilize the spermatogenesis process.

FPT-20 is easily distributed in high concentrations in immune cells. It has natural antibacterial activity, promotes lymphocyte proliferation, and is rapidly consumed during inflammation. The effects show a prominent role in the regulation of the immune system, and there is a high degree of interaction, which requires more research to understand its mechanism, FPT-20 will not be effective in the absence of one of the components selected to participate in the test.

FPT-20 will reach its therapeutic effect after 6-12 months. After 6-12 months, an amount of progressively motile sperm was found in the semen.

According to research, FPT-20 created a homeostasis, protecting cell membranes, cutting off the cell's inflammatory chain, and preventing transcription and translation errors. The mediators regulated the protective responses in the body. Cytokines that have a beneficial effect through specific receptors, and many other unexplained processes, have altered the spermatogenesis status of the testes. The body will absorb the components in FPT-20 through the small intestine wall, this metabolism has created a significant amount of B lymphocytes to provide for the process of restoring the function of the testicles. An appropriately calculated dose of FPT-20 is provided during the treatment, using precursors, enzymes, and flavonoids available in nature to supplement and interfere with biochemical processes taking place in the body. The extracts in the preparation should be used regularly (\>6 months) until the therapeutic purpose is achieved. The product has offered hope to patients who are unable to produce sperm from spermatogonia (because the process has been disrupted). Stabilize the semen pH within good limits, to produce high-quality sperm as well as to achieve efficiency into egg penetration.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spermatogenesis and Semen Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

The number of infertile people after recruitment was divided into 2 groups.

* Spermatogenesis.
* Male infertility group due to lack of sperm.
Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

The number of infertile people after recruitment was divided into 2 groups.

* Spermatogenesis.
* Male infertility group due to lack of sperm.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FPT-20

FPT-20 should be used regularly (\>6 to 12 months) until the therapeutic purpose is achieved.

Group Type EXPERIMENTAL

FPT-20

Intervention Type DRUG

FPT-20 should be used regularly, the daily maintenance dose is 1 tablet once a day(\>6 to 12 months) until the therapeutic purpose is achieved.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FPT-20

FPT-20 should be used regularly, the daily maintenance dose is 1 tablet once a day(\>6 to 12 months) until the therapeutic purpose is achieved.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The selected person has evidence of spermatogenesis disorder, no sperm, and weak sperm that do not meet the standards in terms of quantity and quality.
* There are signs of orchitis.
* Accepting patients with other comorbidities such as metabolic diseases, congenital or acquired immunodeficiency, HIV/AIDS, HBV, HCV, and Tuberculosis.

Exclusion Criteria

* Do not select patients with advanced cancer.
Minimum Eligible Age

25 Years

Maximum Eligible Age

40 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

TRAN MINH DUC, MD

UNKNOWN

Sponsor Role collaborator

Trieu, Nguyen Thi, M.D.

INDIV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nguyen Thi Trieu, Dr.

Role: STUDY_CHAIR

Trieu, Nguyen Thi, M.D.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Saigon Biopharma LLC

Wilmington, Delaware, United States

Site Status

Saigon Biopharma Company Limited

Hồ Chí Minh, Ho Chi Minh City, Vietnam

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Vietnam

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Therapy to spermatogenesis

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.